N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide interaction by Castro, Sonia et al.
 1 
N-Benzyl 4,4-disubstituted piperidines as a potent class of influen-
za H1N1 virus inhibitors showing a novel mechanism of hemagglu-
tinin fusion peptide interaction  
 
Sonia de Castro,a,1 Tiziana Ginex,b,1 Evelien Vanderlinden,c,1 Manon Laporte,c Annelies Stevaert,c 
José Cumella,a Federico Gago,d María José Camarasa,a F. Javier Luque,b,* Lieve Naesens,c,* and 
Sonsoles Velazqueza,* 
 
a Instituto de Química Médica (C.S.I.C.), Juan de la Cierva 3, E-28006 Madrid, Spain 
b Departament de Nutrició, Ciències de l’Alimentació I Gastronomia, Institut de Biomedicina 
(IBUB) and Institut de Química Teòrica i Computacional (IQTCUB), Facultat de Farmàcia i 
Ciències de l’Alimentació, Universitat de Barcelona, Santa Coloma de Gramenet, Spain  
c Rega Institute for Medical Research, KU Leuven – University of Leuven, B-3000, Belgium  
d Área de Farmacología, Departamento de Ciencias Biomédicas, Unidad Asociada al IQM-CSIC, 
Universidad de Alcalá, E-28805 Alcalá de Henares, Madrid, Spain 
* Corresponding authors. 
E-mail: iqmsv29@iqm.csic.es (SV), lieve.naesens@kuleuven.be (LN), fjluque@ub.edu (FJL) 





The influenza virus hemagglutinin (HA) is an attractive target for antiviral therapy due to its essen-
tial role in mediating virus entry into the host cell. We here report the identification of a class of N-
benzyl-4,4,-disubstituted piperidines as influenza A virus fusion inhibitors with specific activity 
against the H1N1 subtype. Using the highly efficient one-step Ugi four-component reaction, a di-
verse library of piperidine-based analogs was synthesized and evaluated to explore the structure-
activity relationships (SAR). Mechanistic studies, including resistance selection with the most active 
compound (2) demonstrated that it acts as an inhibitor of the low pH-induced HA-mediated mem-
brane fusion process. Computational studies identified an as yet unrecognized fusion inhibitor bind-
ing site, which is located at the bottom of the HA2 stem in close proximity to the fusion peptide. A 
direct π-stacking interaction between the N-benzylpiperidine moiety of 2 and F9HA2 of the fusion 
peptide, reinforced with an additional p-stacking interaction with Y119HA2, and a salt bridge of the 
protonated piperidine nitrogen with E120HA2, were identified as important interactions to mediate 
ligand binding. This site rationalized the observed SAR and provided a structural explanation for the 
H1N1-specific activity of our inhibitors. Furthermore, the HA1-S326V mutation resulting in re-
sistance to 2 is close to the proposed new binding pocket. Our findings point to the N-benzyl-4,4,-
disubstituted piperidines as an interesting class of influenza virus inhibitors, representing the first 
example of fusion peptide binders with great potential for anti-influenza drug development. 
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Each year, influenza A and B viruses are responsible for 3-5 million severe cases and 290,000-
650,000 deaths worldwide [1]. The death toll rises sharply during influenza pandemics, like the 2009 
pandemic that was caused by a novel swine-origin A/H1N1 virus [2]. Though widely used and rec-
ommended, influenza vaccination is limited by suboptimal effectiveness, the need for annual injec-
tion and possibility of antigen mismatch [3]. The complementary strategy, antiviral therapy, is cru-
cial to treat and prevent complicated influenza infections, which typically develop in aged, chroni-
cally ill or hospitalized individuals [4]. Nowadays, neuraminidase inhibitors are the only effective 
drug class that is widely available. Hence, there is an urgent need for new influenza blockers with a 
distinct mode of action. Some of these are under early or advanced clinical evaluation [5,6]. 
The trimeric hemagglutinin (HA) glycoprotein is an attractive drug target due to its critical and dual 
role in virus entry [7]: i) the HA globular head recognizes sialylated cell surface glycans and medi-
ates virus attachment [8], and ii) HA is required for membrane fusion after the virus particles have 
entered by endocytosis. Upon acidification of the early into late endosomes, the low pH (~5) triggers 
radical refolding of HA, resulting in release of its hydrophobic fusion peptide and fusion of the viral 
and endosomal membranes [7]. Next, the viral genome segments traffic via the fusion pore into the 
nucleus to proceed with virus replication. Over the years, several HA inhibitors have been explored 
to target either the HA-host cell interaction through binding to the sialic acid binding pocket, or pre-
vent the membrane fusion process with peptide and nonpeptide-based HA fusion inhibitors [9]. 
Since the low pH-induced refolding of HA involves the entire HA stem structure, HA fusion inhibi-
tors may, at least in theory, target different HA binding pockets. Thus far, two major binding sites 
localized in the HA1-HA2 stem region have been identified and validated by structural data.  
The first crystallographic structure of HA bound to a group 2-specific small fusion inhibitor, tert-
butylhydroxyquinone (TBHQ; Fig. 1), was solved in 2008 [10]. TBHQ binds in a hydrophobic 
pocket located at the stem region of HA formed upon partial unfolding of the C-terminal region of 
the HA2 B helix (site A in Fig. 1). This site is also targeted by arbidol (umifenovir; Fig. 1), a broad-
spectrum antiviral compound approved in Russia and China [11], and by N-cyclohexyltaurine [12]. 
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It was also proposed as the binding site for a class of group 1-specific aniline-based inhibitors (such 
as 9d in Fig. 1; [13]). On the other hand, guided by the binding mode of the anti-HA stem antibody 
CR6261, the conserved HA1-HA2 fusion region of group 1 HAs is targeted by JNJ4796 (site B in 
Fig. 1; [14]), and the cyclic peptide CP141037 (not shown; [15]). Finally, MBX2329 and MBX2546 
(Fig. 1) were found to inhibit group 1 A/H1N1 and A/H5N1 strains through binding to non-
overlapping sites in the stem region of HA [16]. 
 
 
Fig. 1. Location of two known binding sites for HA fusion inhibitors. The site A binders TBHQ and 
arbidol are shown as blue and green spheres, respectively, while the site B binder JNJ4796 is dis-
played as magenta spheres. The fusion peptide is colored in red.  
 
 
In this report, a novel class of piperidine-based HA fusion inhibitors is presented. The choice of a 
piperidine heterocycle was motivated by its pivotal role in drug design [17]. Recently reported 
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pharmacological uses of diverse substituted piperidine derivatives include coronary heart disease, 
anticancer, antivirals, and antinociceptives, among others [18-22].  In fact, one of the most frequently 
used non-aromatic ring systems in small molecule drugs is the piperidine ring [23], particularly 1,4-
disubstituted piperidine, due to its easy synthesis and lack of stereochemical issues. A few years ago, 
we described [24] a structurally distinct series of 1,4,4-substituted piperidine derivatives, which were 
efficiently synthesized by means of the Ugi four-component reaction. These compounds of general 
formula I can be easily generated from amines, isocyanides, N-substituted piperidones and amino 
acids as ketone and carboxylic components (Fig. 2A). Hence, starting from commercially available 
reagents, five points of diversity can be introduced in a one-step reaction. 
 
 
Fig. 2. Synthesis and chemical structures of 1,4,4-trisubstituted piperidine-based compounds. (A) 
Synthetic pathway of the target compounds I by Ugi-4C reaction. (B) Chemical structures of proto-
type compound 1 (hit) and its fluorine analogue 2.  
 
 
During broad biological evaluation, we noticed that 1 (Fig. 2B) exhibited low micromolar activity 
against influenza A/H1N1 virus. Starting from this hit compound, we here report the synthesis of an 













































antiviral mechanism of action. The most active compound, i.e. the fluorine derivative 2 (Fig. 2B), 
was selected for mechanistic studies including selection of resistant influenza virus mutants and in-
fluenza HA polykaryon assays. The biological findings were rationalized by in silico predictions of 
the binding mode within the viral HA protein, using molecular simulations. A new binding pocket 
that is located close to the fusion peptide at the HA2 subunit is proposed. To the best of our 
knowledge, this pocket has not been so far explored by any inhibitors targeting the HA-mediated 
fusion process. Overall, the results show that the N-benzyl 4,4-disubstituted piperidine compounds 
represent a structurally promising scaffold for the design of influenza virus fusion inhibitors. 
 
2. Results and Discussion 
2.1. Chemistry 
The Ugi four-component reaction is one of the most prominent isocyanide-based multicomponent 
reactions due to its versatility, atom economy and experimental simplicity, enabling the conversion 
of isocyanides, amines, aldehydes (ketones) and carboxylic acid into a great variety of bis-amide 
derivatives [25-27]. We previously applied this reaction for the efficient synthesis of a structurally 
diverse library of 1,4,4-substituted piperidine bis-amide derivatives (Fig. 2A; [24]). Antiviral evalua-
tion of these compounds allowed us to identify the N-benzyl 4,4-dipeptide piperidine analogue 1 
(Fig. 2B) as a promising hit endowed with low micromolar activity against influenza A/PR/8/34 
(A/H1N1) virus. The inhibitory activity was even 5-fold higher for the 4-fluorobenzyl analogue 2 
(Fig. 2B). Hence, we decided to synthesize a large series of piperidine-based analogues by modify-
ing the R1-R5 substituents and investigating the SAR for influenza virus. 
The general synthetic route for these novel piperidine analogues is depicted in Fig. 2A. The synthe-
sis was accomplished in a relatively easy way via the Ugi four-component reaction with moderate to 
good yields. Commercially available N-substituted 4-piperidone (A), isocyanides (B), aromatic and 
aliphatic primary amines (C) and a variety of polar, hydrophobic or aromatic natural L-amino acids 
as carboxylic acids (D) were allowed to react in methanol at room temperature over 72 h, followed 
by chromatographic purification. In this work, 27 novel piperidine analogues were synthesized, fully 
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characterized as the corresponding free amine derivatives, and evaluated for antiviral activity. Using 
the Sirius T3 apparatus (Supplementary Material Fig. S1), a pKa value of 7.5 was measured for 
compound 2, indicating that its piperidine moiety should be positively charged at the acidic pH (~5) 
of late endosomes. We also evaluated the chemical stability at this acidic pH for the N-Boc or N-Cbz 
groups in the most active compounds 2 and 34. They proved very stable after 72 h incubation in ace-
tonitrile:acetate acidic buffer solutions (pH=5.5), which mimic the acidic conditions in the endoso-
mal lumen. 
2.2. Analysis of anti-influenza virus activity 
Compounds 1 and 2 served as the starting points for an extensive SAR exploration against influenza 
virus, performed in MDCK cells infected with strain A/PR/8/34 (A/H1N1). For analysis of the anti-
viral results (Table 1), the compounds were organized in three subseries with modifications at i) R1 
or R2, ii) R3, and iii) R4 or R5. 
In the first subseries, which comprises compounds retaining the 4-fluorobenzyl unit of 2, the effect 
of R1 and R2 substituents was assessed using a variety of commercially available N-substituted pi-
peridones (A) and isocyanides (B). Elimination of the N-1-benzylpiperidine nucleus (3) resulted in 
complete loss of activity. The antiviral activity was significantly reduced when the R1 benzyl was 
missing (4) or replaced by cyclohexyl (6) or methyl (5), and totally lost in analogues having a cyclo-
hexyl (6), phenyl, 4-Cl-phenyl or phenylethyl at R1 (7 and 8). Thus, an N-1-benzyl piperidine sub-
stituent at R1 was absolutely required for activity. Also, the R2 benzyl group proved to be critical 
since its replacement by cyclohexyl (9), t-butyl (10) or tosylmethyl (11) was detrimental.  
In the second subseries, the influence of the R3 substituent was investigated by varying the nature of 
the primary amine (C). Again, the benzyl moiety appeared a critical structural element since its elim-
ination (12) or replacement by alkyl (14), cyclopropyl (15) or phenylaminoethyl group (16) was det-
rimental for the inhibitory activity, while a methyl substituent was partially (13) tolerated. Besides, 
various substituents with different electronic properties were introduced at the R3 aromatic substitu-
ent. At position 4, a halogen was clearly preferred (cfr. 5-fold higher activity of 2 compared to 1), 
since the analogues carrying a methyl (17) or nitro group (19) were less active, while trifluoromethyl 
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(18) was detrimental. In line with the positive effect of the 4-F atom, even slightly higher potency 
was seen with the 4-chloro analogue 20. The 2-F derivative was equipotent to the unsubstituted 
compound 1, while a 3-F atom had intermediate effect. The 3,4-disubstituted fluoro compound 23 
was inactive.  
Finally, the third subseries explored changes at R4 (mostly NHBoc or NHCbz) and R5, including a 
variety of polar, hydrophobic or aromatic natural L-amino acid substituents. Substitution at R4 
proved advantageous yet not absolutely required (25). The difference between NHBoc and NHCbz 
was not clear, since NHBoc was preferred in one case (compare 2 to 26) while NHCbz was superior 
in another case (compare 34 to 1). An amino group at R4 yielded a compound (24) with strong anti-
viral activity but pronounced cytotoxicity; hence, this substitution was not further explored. Regard-
ing the R5 group in Boc-protected amino acids, the antiviral potency was reduced by a factor of 5 
when the Asp(OMe) [= CH2COOMe] moiety in lead compound 2 was replaced by Ala (27) or 
Glu(OMe) [= CH2CH2COOMe] (28). Whereas replacing the Asp(OMe) by Asn [= CH2CONH2] did 
not alter the antiviral potency (31 and 33), a detrimental effect was seen when the methyl ester was 
hydrolysed to free acid (Asp 30; R5 = CH2COOH). An alkyl (Ile 32) or an aromatic (Phe 29) moiety 
at R5 was not tolerated in these close analogues of prototypes 1 and 2. Remarkably, a different SAR 
trend was seen in the compound series with a cyclopropyl at R3, since the Asp(OMe) analogue 34 
was only 2- to 4-fold more active than the three analogues 35-37 with a hydrophobic alkyl (35 and 
36) or an aromatic R5 moiety (Phe 37). Besides, derivatives 36 and 37 represent the only active 
compounds with an alkyl substituent at R2 (t-butyl). 
The window between activity and cytotoxicity was estimated by calculating the ratio between CC50 
and EC50, defined as the selectivity index (SI). The compounds showing superior selectivity were 34 
[SI: 40], 31 [SI: 26], 2 [SI: 18], 35 [SI: 8] and 36 [SI: 13]. Vice versa, the following compounds 
proved quite active (EC50 < 10 µM) yet less selective [SI ≤ 10]: 1, 33, 37, 35, 28, 20, 22 and 21. The 
most cytotoxic compounds proved to be the 4-Cl benzyl analogue 20 and the R4 deprotected free 
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When the effect was determined on a panel of influenza A and B viruses (data not shown), the inhi-
bition proved limited to the A/PR/8/34 strain. No activity was observed against pandemic 2009 virus 
(which alike A/PR/8/34 belongs to the A/H1N1 subtype), nor the A/H3N2 subtype and influenza B 
virus. On the other hand, compound 2 proved also effective in A/PR/8/34-infected Calu-3 cells, 
which are a relevant model for human airway epithelial cells. Namely, the anti-influenza virus EC50 
value in Calu-3 cells was 1.8 µM based on CPE scoring and 3.0 µM when assessed by MTS assay 
(data not shown). 
2.3. Mechanism of inhibitory activity 
The most active compound 2 was selected for mechanistic investigations, starting with one-cycle 
time-of-addition experiments. Compound addition time was varied relative to virus infection and the 
reduction in viral vRNA synthesis was monitored at 10 h p.i. The influenza virus entry process con-
sists of virus binding to the cells, uptake in and release from acidic endosomes, and import of viral 
ribonucleoprotein (vRNP) complexes into the nucleus, in total taking about 1 h in MDCK cells [28]. 
Hence, the reference compound chloroquine, which acts by increasing the endosomal pH, complete-
ly lost its activity when added at 1 h p.i. (Fig. 3). For ribavirin, an inhibitor of viral RNA synthesis 
[29], the time-of-addition curve was situated beyond 1 h p.i. with the steepest part between 3 and 5 h 
p.i. Nucleozin remained fully effective when added as late as 5 h p.i., consistent with the finding that 
late addition of this agent blocks cytoplasmic traffic of the vRNPs after their nuclear export [30]. For 
2, the curve fully overlapped with that of chloroquine, indicating that its action takes place during 
the endosomal stage of the virus. The low pH inside the endosomes triggers membrane fusion in-
duced by HA, virus uncoating that requires M2 proton channel activity, and weakening of the vRNP-
M1 matrix protein interactions.  
To better define the target, influenza A/PR/8/34 virus was serially passaged in the absence or pres-
ence of 2. Resistant virus emerging at passage #7 was plaque-purified and virus clones were submit-
ted to phenotypic and genotypic analysis. As shown in Table 2, the two clones selected under 2 dis-
played manifest (>40-fold) resistance to 2 while being fully sensitive to ribavirin. Both clones con-




since it was previously detected upon passaging of A/PR/8/34 virus in cell culture and linked to pol-
ymorphism or cell culture adaptation [32]. The resistance to 2 was thus attributed to substitutions 
HA1-S326V and HA2-L99F. This concurred with its HA-subtype dependent activity and, in combi-
nation with the time-of-addition data, suggested that it affects HA-mediated membrane fusion. 
 
 
Fig. 3. Time-of-addition experiments showed that 2 acts during the endosomal stage in influenza 
virus entry. MDCK cells were infected with A/PR/8/34 virus and the compounds were added at dif-
ferent time points ranging from -0.5 h until 8 h p.i. At 10 h p.i., total cellular RNA extracts were 
prepared and viral vRNA was quantified by two-step RT-qPCR. The Y-axis shows the fold increase 
in vRNA relative to the amount added at time zero; the dashed line indicates the increase in the un-
treated virus control. Data are the mean of two independent experiments. 
 
Table 2. Characterization of compound 2-resistant mutant influenza viruses. 
Virus/clonea Residue  
substitutionsb  
Hemolysis pHc Antiviral EC50 (µM)d 
  2 Ribavirin 








ND >100 >100 13 ± 2 21 ± 3 
No cpd/cl1 HA2-T54A 5.3 ± 0.0 4.5 ± 0.1 13 ± 7 15 ± 2 22 ± 3 
Parent viruse - 5.0 ± 0.0 1.9 ± 0.1 2.7 ± 0.4 22 ± 4 31 ± 5 
a A/PR/8/34 virus was serially passaged in MDCK cells in the absence of compound (no cpd control) 
or gradually increasing (up to 25 µM) concentrations of 2. After seven passages, individual virus 
clones were obtained by plaque purification.  
b Substitutions in HA relative to parent virus. Separate amino acid numbering for the HA1 and HA2 




c pH at which 50% hemolysis occurs, relative to the value at pH 4.6.  
d EC50: 50% effective concentration, as determined by the microscopic CPE assay or MTS cell via-
bility assay. 
e Parent allantoic stock of A/PR/8/34 virus, used at the start of the passage experiment. 
Values shown are the mean ± SEM (N ≥ 3). ND, not determined. 
 
 
The precise mechanism was revealed in the polykaryon assay, which monitors cell-cell fusion that is 
provoked by influenza virus HA when its conformation changes at acidic pH. At a concentration of 
100 µM, 2 completely inhibited polykaryon formation in H1 (A/PR/8/34) HA-transfected HeLa cells 
exposed to an acidic buffer of pH 5.2 (Fig. 4). This fusion-inhibiting effect was dose-dependent with 
a 50% inhibitory concentration (IC50) value of 12 µM. The same assay was used to determine which 
of the three HA mutations detected in virus resistant to compound 2 (see above) are responsible for 
the resistance response. In HeLa cells transfected with the HA1-I324T mutant protein, 2 was nicely 
active, and the IC50 value was even lower compared to that of wild-type HA (Fig. 4). On the other 
hand, 2 was totally inactive (IC50 >100 µM) against the HA1-S326V and HA2-L99F mutants. 
As demonstrated by us in a previous study [33], resistance to influenza virus fusion inhibitors can 
occur at two different levels. A first type of mutations, located in the inhibitor’s binding pocket with-
in HA, directly affects the HA binding capacity of the molecule. Alternatively, HA mutations that 
increase the fusion pH render the HA protein less stable, thereby counteracting the HA-stabilizing 
effect of the fusion inhibitor. This second possibility was investigated by determining the hemolysis 
pH of the mutant virus selected under 2. As such, cell culture passaging without compound increased 
the hemolysis pH by 0.3 pH units, compared to the parent A/PR/8/34 virus grown in eggs (Table 2). 
Virus that arose under 2 had the same hemolysis pH (i.e., 5.3) as the no compound control, meaning 
that HA stability at low pH is not affected by the combination of substitutions HA1-I324T, HA1-






Fig. 4. Inhibition of membrane fusion induced by wild-type or mutant forms of H1 HA. Compound 
2 prevents polykaryon formation in HeLa cells expressing wild-type H1 HA (A/PR/8/34) and ex-
posed to a pH 5.2 buffer. Photographs, from left to right: cells treated with 100 µM of 2 and exposed 
to pH 5.2; mock-treated cells exposed to pH 5.2; mock-treated cells exposed to pH 7.0. The Table 
shows the IC50 values for inhibition of polykaryon formation induced by wild-type and mutant HA 
proteins (mean ± SEM; N= 3). 
 
Finally, compound 2 was further profiled by performing some additional mechanistic experiments. 
The potential effect on HA-mediated virus binding to sialylated cell surface glycans was evaluated 
in a virus binding experiment in MDCK cells kept at 4 °C. Compound 2 proved to have no effect 
(data not shown) whereas the sialylated lipid compound NMSO3 [34], at a concentration of 200 µM, 
produced 96% inhibition of virus binding to MDCK cells. We also investigated whether the com-
pounds might inhibit a cellular protease associated with influenza virus entry or HA functionality. 
The HA1-I324T and HA1-S326V substitutions in resistant virus obtained under compound 2 are ly-
ing in the cleavage loop of the HA0 precursor protein. In order to become fusion-competent, HA0 
requires cleavage into its HA1 and HA2 polypeptides, by serine proteases trypsin and human airway 
trypsin-like protease (HAT) [35]. We therefore tested whether the compounds could possibly act by 
inhibiting these proteases (Supplementary Material Table S1). We included three cathepsin enzymes, 
i.e. cathepsin F used as the commercially available analogue of cathepsin W [36], a cysteine protease 




cathepsin B and cathepsin L because of a reported link with influenza virus replication [38]. Enzy-
matic experiments were carried out with the methyl ester 2 as well as the free carboxylic acid that 
might be released intracellularly, i.e. 30, respectively, as well as highly active compounds 31 and 34. 
Neither of these molecules produced any inhibitory effect on the five proteases tested. For compari-
son, 1 µM of camostat gave ~90% inhibition of trypsin and HAT and the same level of inhibition 
was seen with 1 µM of E64 tested against cathepsin B and cathepsin L; for cathepsin F, the inhibi-
tion was ~50% (data not shown). 
2.4. Structural and molecular modeling analysis 
Since 2 exerts its inhibitory activity by interfering with HA-mediated membrane fusion, its potential 
binding to sites A and B (Fig. 1) was explored by docking computations using Glide [39, 40]. To this 
end, the X-ray structure of HA (H3 subtype) bound to TBHQ (PDB entry 3EYM) was used as tem-
plate to generate the 3D model for A/PR/8/34 HA in an “open” conformation, which is characterized 
by the unfolding of the C-terminal region of helix A. This model was used to perform docking simu-
lations in site A. On the other hand, the PDB structure 1RU7 [41] of A/PR/8/34 HA in apo form was 
used for the binding to site B.  
Three and one main clusters were found for sites A and B, respectively, with scores ranging from -
8.2 to -7.2 Kcal mol-1 for site A and -3.8 Kcal mol-1 for site B (Supplementary Material Fig. S2). In 
the predicted pose for 2 (cluster 1) bound to site A, the N-1-benzylpiperidine moiety (R1) forms a 
hydrogen bond (HB) between the protonated nitrogen and the backbone oxygen of K51HA2, and the 
benzylamide group (R2) is surrounded by Leu residues at the bottom of the cavity, whereas no stabi-
lizing interactions were observed for R3, R4 and R5, which are exposed to the solvent outside the 
binding pocket. However, this binding mode cannot explain the SAR discussed above, such as the 
loss of inhibitory activity upon replacement of the benzyl moiety (R1) by phenyl (7), or the changes 
in activity found upon chemical modifications of R3, R4, and R5. In site B, 2 partially fills the hydro-
phobic groove formed by the HA1 and HA2 subunits, as the N-1-benzylpiperidine (R1) and benzyla-
mide groups (R2) partially match some residues of the cyclic peptide CP141037. Nevertheless, no 




pose (-3.8 Kcal mol-1). Furthermore, superposition of 2 with JNJ47962 revealed weak chemical re-
semblance in the binding motif to site B (Supplementary Material Fig. S2). 
Hence, an alternative binding pocket was searched through pocket analysis using Fpocket [42]. This 
led to the identification of a putative binding site located at the bottom of HA in a pocket shaped by 
the three HA2 helices (Fig. 5). In this pocket, 2 was anchored through several interactions (Fig. 6A), 
including i) a salt bridge between the protonated nitrogen of the benzylpiperidine unit (R1) with 
























Three independent 100 ns MD simulations were performed to investigate the structural stability of 
this novel HA-2 complex. The binding mode was maintained during the simulations, as noted by the 
stability of the positional root-mean square deviation of both the protein and the ligand (Supplemen-
tary Material Fig. S3), and the comparison of the binding mode at the beginning and end of the 
simulation (Fig. 6). The salt bridge formed between the protonated piperidine of 2 and E120HA2 is 
maintained in all cases, with an average N…O distance close to 3.3 Å, which is enlarged to 6.5 Å due 
to the insertion of a water molecule only in the last 20ns of the trajectory obtained for replica 1 (d6 
in Supplementary Material Fig. S4). Regarding the π-stacking interaction between the benzylpiperi-
dine moiety of 2 and the benzene ring of F9HA2, a concerted rearrangement of the aromatic rings 
enabled the ligand to form an additional π-stacking interaction with Y119HA2 (Fig. 6B). The distance 
between the stacked aromatic rings (d4 and d5 in Supplementary Material Fig. S4) varied from 3.5 
to 4.4 Å. 
 
 
Fig. 6. Representation of (A) the energy-minimized structure of compound 2 (shown as sticks with 
carbon atoms coloured in green) after docking in site C of HA, and (B) the last snapshot obtained 
from the MD simulation of the HA-2 complex. Selected residues involved in protein-ligand interac-






The 4-F-benzene (R3) unit fills a cavity formed by the side chains of K116HA2, E120HA2, Y119HA2, 
and S124HA2 (Fig. 6; see also Supplementary Material Fig. S5 and S6). The distance of the fluorine 
atom in the 4-F-benzene unit to the closest atoms in these residues varies between 3.6 and 5.4 Å, 
suggesting a limited tolerance for accommodating larger substituents. This may explain the slight 
decrease in antiviral activity observed upon replacement of 4-F in 2 by 4-Me in 17 (i.e, 3.6-fold less 
potent), and drastic loss of activity upon substitution by 4-CF3 in 18, as well as the similar activity 
observed between 2 and its 3-F analogue (i.e., a 2.1-fold increase in EC50; Table 1). Furthermore, the 
benzene ring of R3 is located at around 5 Å from the protonated amino group of K123HA2, which in 
turn forms a stable H-bond with the carbonyl oxygen of NH-Boc (R4), as noted in average values of 
2.9±1.0, 2.5±0.6 and 2.5±0.5 Å for the three replicas (Fig. 6). 
The tight-packed arrangement of the ligand should shield the network of salt bridges formed be-
tween the protonated piperidine nitrogen of 2 and the carboxylate group of E120HA2, which in turn is 
stabilized by contacts with K116HA2, from the bulk solvent, thus reinforcing these interactions. This 
is reflected in the favorable binding free energy values obtained from MM/GBSA calculations, espe-
cially for replicas 1 and 3 (-24.4 ± 4.8 and -25.7 ± 4.6 Kcal mol-1; Supplementary Material Table 
S2). Furthermore, the π-stacking of the N-benzyl ring with both F9HA2 and Y119HA2 should promote 
the stabilization of the fusion peptide. Remarkably, the stabilizing effect spreads up to G1HA2 
through a network of intramolecular interactions, especially involving L2HA2, G4HA2, A5HA2 and 
G8HA2 (Supplementary Material Fig. S7), which were identified by site-directed mutagenesis as crit-
ical for the stabilization of the fusion peptide [43]. Indeed, lower fluctuations were observed for the 
residues of the fusion peptide interacting with the benzyl moiety (R1) of 2 (values of 0.87 ± 0.1, 0.89 
± 0.13 and 0.89 ± 0.1, respectively, determined for the three independent MD simulations) compared 
to the fluctuations of the same residues in the other two chains of HA (values of 1.0 ± 0.2/1.0 ± 0.2, 
1.3 ± 0.3/1.1 ± 0.2 and 1.11 ± 0.3/1.2 ± 0.1 for monomers not involved in the π-stacking interaction; 
Supplementary Material Fig. S7). The key role of the N-1-benzylpiperidine moiety is also noted in 




phenyl (7) or phenylethyl (8), since these would imply a loss of the stacking interaction, as well as 
by the reduced activity found upon replacement by H (4) or methyl (5).  
To confirm the suitability of this binding mode, compounds 38-40 were rationally designed and syn-
thesized to determine their antiviral activity (Table 1). The presence of a quaternary nitrogen in 40, 
though preserving the positive charge of the ligand should affect the salt bridge with E120HA2, lead-
ing to a drastic reduction in inhibitory activity, as confirmed experimentally (EC50 >100; Table 1). 
On the other hand, 38 and 39 were chosen to explore the ability of the benzyl ring attached to the 
piperidine nitrogen to fill the pocket between F9HA2 and Y119HA2, whose size is hindered by residues 
A5HA2 and V115HA2. Accordingly, whereas the insertion of a single F atom in meta position (38) may 
fill the void space between the benzene and G134HA2, the insertion of two F atoms (39) would be 
penalized by unfavorable repulsion with the lone pairs of carbonyl oxygens in V115HA2 and K116HA2 
(Supplementary Material Fig. S4). Indeed, the biological evaluation revealed that the antiviral activi-
ty of 2 was retained in compound 38, but abolished in 39 (Table 1).  
Finally, the suitability of this binding site is reinforced by the fact that it explains the selectivity of 2 
for the A/PR/8/34 influenza virus strain and lack of activity against 2009 pandemic H1N1 virus. 
Thus, the HA sequence alignment of A/PR/8/34 H1N1 and A/Virginia/ATCC3/2009 H1N1 (Supp-
plementary MaterialFig. S8) reveals the preservation of the residues that shape site C, except for 
replacement of K123HA2 in A/PR/8/34 by R in A/Virginia/ATCC3/2009. Even though at first sight 
this appears to be a conserved mutation, this substitution in the three monomers of trimeric HA trig-
gers a substantial reduction in the volume of the cavity, which would affect the binding of compound 
2 to site C (Fig. 7). Interestingly, the analysis of HA sequences retrieved from 3DFlu [44] for differ-
ent subtypes of group 1 (H1, H2, H5, H6, H8 and H9) and group 2 (H3, H7 and H10) HA proteins 
(Supplementary Material Fig. S9) revealed that the K123HA2R mutation is not only present in both 
HA groups, but also frequently accompanied by other changes in site C, which could explain why 
these compounds are specific against the H1 HA subtype (Supplementary Material Fig. S10). On the 




protein resistant to compound 2, is mapped closely to the proposed new binding pocket (Supporting 
Information Figure S11).  
 
 
Figure 7. Representation of the cavity filled by compound 2 in site C for (left) A/PR/8/34 (deter-
mined from the last snapshot of the MD simulation), and (right) after replacement of K123HA2 by R, 
reflecting the sensitivity of size and shape of site C to changes in residue composition. The fusion 
peptide is shown as yellow cartoon. Interatomic distances (Å) are shown in red. The cavity was de-




We here report the synthesis and antiviral evaluation of 40 N-benzyl-4,4-disubstituted piperidines, 
which were easily synthesized by an Ugi four-component reaction. Several displayed low-
micromolar activity against A/H1N1 influenza virus (i.e., the A/PR/8/34 strain) but not the A/H3N2 
subtype. Mechanistic studies including virus resistance selection and polykaryon assays with com-
pound 2 demonstrated that it represents a new class of H1 HA-specific membrane fusion inhibitors. 
The inhibitory activity is proposed to be mediated through binding to a new site in the HA2 subunit 
close to the fusion peptide, which is so far unexplored to design influenza virus fusion inhibitors. 
Remarkably, a direct π-stacking interaction of the N1-benzylpiperidine moiety with a F9HA2 residue 
located on the fusion peptide is reinforced by the formation of a second π-stacking with Y119HA2. 
The proposed binding model successfully rationalized the SAR results and the observed selectivity 
of 2 for the A/PR/8/34 influenza virus strain. Interestingly, the 2-resistant HA1-S326V mutation lies 




The antiviral efficacy of the compounds is limited to the A/PR/8/34 H1N1 virus so far, thus reducing 
the practical therapeutic application of this type of inhibitors. However, the unique binding mode 
proposed for compound 2, which may directly stabilize the fusion peptide leading to an alternative 
inhibition mechanism in comparison with reported small-molecule fusion inhibitors, deserves further 
study. These compounds therefore appear to be promising hits, although two major challenges need 
to be dealt with. The first improvement would be search for chemical modifications able to form 
interaction with all three fusion peptides in the trimeric structure of HA, which would likely enhance 
the inhibitory potency. The second would be to obtain inhibition of other HA subtypes to confer 
broad anti-influenza A virus activity. Finally, given their direct interaction with the fusion peptide, 
these compounds may also serve as a scaffold to design chemical tools for exploration of the fusion 
process, more specifically the molecular events that occur during low pH-induced HA refolding 
leading to release of the fusion peptide. 
 
4. Experimental section 
4.1. Chemistry 
The chemical synthesis and characterization of novel 1,4,4-trisubstituted piperidine analogues 3, 5-
11, 17-23, 25-29, 31, 38 and 39 were carried out according to an Ugi four-component reaction as 
described below. The chemical synthesis and characterization of novel compound 4, 24, 30 and 40 
were described in Supplementary Material. For 1, 2 and the remaining piperidine compounds, the 
synthesis was reported in detail elsewhere [24]. The reference compounds ribavirin, chloroquine and 
nucleozin were from commercial sources. The sulphated sialyl lipid NMSO3 was a generous gift 
from G. Wright (Microbiotix, Worcester, MA).  
4.2. General information 
Microanalytical results obtained with a Heraeus CHN-O-RAPID were within 0.4% of the theoretical 
values. Electrospray mass spectra were measured on a quadrupole mass spectrometer equipped with 
an electrospray source (Hewlett Packard, LC/MS HP 1100). Analytical thin-layer chromatography 




chromatography with silica gel 60 (230-400 mesh) (Merck), by preparative centrifugal circular thin-
layer chromatography (CCTLC) on a Chromatotron (Kiesegel 60 PF254 gipshaltig (Merck), layer 
thickness of 1 mm, flow rate of 5 mL/min) or by MPLC using SNAP 12 g KP-C18-HS cartridges in 
an Isolera One system (Biotage). The purity of the compounds was analyzed using an analytical Ag-
ilent Technologies (model 1120 Compact LC) ACE 5 C18-300 column (150 mm x 4.6 mm). Gradi-
ent conditions were: mobile phase CH3CN/H2O (0.05% TFA); flow rate, 1 mL/min; detection, UV 
(254 and 217 nm). All retention times are quoted in minutes. HPLC–MS was performed on an 
HPLC Waters 2695 instrument connected to a Waters Micromass ZQ 2000 spectrometer, and a pho-
todiode array detector. The column used was a Sunfire C18 (4.6 mmx50 mm, 3.5 mm), and the flow 
rate was 1 mLmin-1. NMR spectra were recorded with Varian Inova-300, Varian Inova-400 or Vari-
an System-500 spectrometers operating at 300, 400, or 500 MHz for 1H NMR, and at 75, 100, or at 
125 MHz for 13C NMR with Me4Si as an internal standard. The purity of novel compounds was also 
determined to be >95% by elemental analysis. Chemicals and reagents were obtained from commer-
cial sources and used without further purification. 
4.3.General synthetic procedure for the Ugi reaction 
To a solution of the ketone (1.32 mmol) in methanol (2 mL), 2 equivalents of the corresponding 
amine, 2 equivalents of the amino acid and 2 equivalents of the isocyanide were successively added. 
The resulting mixture was stirred at room temperature for 4 days. Then, a 1.2 M solution of HCl in 
MeOH was added and the mixture was stirred at room temperature for 30 min. The solvent was re-
moved under reduced pressure. The residue was redissolved in ethyl acetate and was successively 
washed with saturated NaHCO3 (3 x 10 mL) and brine (3 x 10 mL). The organic phase was dried 
(MgSO4), filtered and evaporated to dryness. The final residue was purified by flash column chro-
matography (hexane:ethyl acetate, 4:1 to 0:1) to give the novel N-benzyl 4,4-disubstituted piperidine 






Following the general procedure, a solution of acetone (0.22 mmol, 0.016 mL), 4-fluorobenzylamine 
(0.44 mmol, 0.071 mL), Boc-Asp(OMe)-OH (0.44 mmol, 122 mg) and benzyl isocyanide (0.44 
mmol, 0.066 mL) in MeOH (2 mL) was reacted. The final residue was purified to give 3 (46 mg, 
40%) as a white foam. 1H NMR [500 MHz, CDCl3] δ: 7.38 (dd, J = 8.5, 5.2 Hz, 2H), 7.28 (m, 6H), 
7.02 (t, J = 8.5 Hz, 2H), 6.35 (d, J = 5.9 Hz, 1H), 5.08 (d, J = 9.2 Hz, 1H), 4.80 (m, 3H), 4.42 (qd, J 
= 14.9, 5.7 Hz, 2H), 3.47 (s, 3H), 2.79 (dd, J = 16.5, 8.9 Hz, 1H), 2.60 (dd, J = 16.5, 4.8 Hz, 1H), 
1.50 (s, 3H), 1.45 (s, 3H), 1.35 (s, 9H). 13C NMR [100 MHz, CDCl3] δ: 174.51, 172.01, 171.97, 
162.16 (d, J = 245.7 Hz), 154.62, 138.88, 133.91 (d, J = 3.3 Hz), 128.54, 128.51, 128.13, 128.07, 
127.72, 127.25, 115.80 (d, J = 21.6 Hz), 80.41, 63.61, 51.90, 48.25, 47.62, 43.76, 37.72, 28.26, 
25.22, 23.84. MS (ES+) m/z 530.4 (M + 1)+ HPLC 9.72 min (98%) (H2O/CH3CN from 15/85 to 
0/100 in 10 min, flow rate of 1 mL/min). Elemental analysis for C28H36FN3O      (C, H, F, N): Calcu-
lated: C, 63.50; H, 6.85; F, 3.59; N, 7.93; Found: C, 63.39; H, 6.90; F, 3.55; N, 7.92. 
4.5. Methyl (S)-4-((4-(benzylcarbamoyl)-1-methylpiperidin-4-yl)(4-fluorobenzyl)amino)-3-((tert-
butoxycarbonyl)amino)-4-oxobutanoate (5)  
Following the general procedure, a solution of N-methylpiperidone (0.21 mmol, 0.026 mL), 4-
fluorobenzylamine (0.58 mmol, 0.066 mL), Boc-Asp(OMe)-OH (143 mg,0.58 mmol)and benzyl 
isocyanide (0.58 mmol, 0.071 mL) in MeOH (2 mL) was reacted. The final residue was purified to 
give 5 (110 mg, 90%) as a white foam. 1H NMR [500 MHz, CDCl3] δ: 7.38-7.28 (m, 7H); 7.24 (d, J 
= 7.7 Hz, 2H); 6.99 (t, J = 8.4 Hz, 2H); 6.70 (t, J = 5.0 Hz, 1H); 4.99 (d, J = 9.0 Hz, 1H); 4.81-4.71 
(m, 2H); 4.37 (m, 3H, 8); 3.50 (s, 3H); 2.86-2.73 (m, 4H); 2.65-2.45 (m, 2H); 2.35-2.25 (bs, 3H); 
2.24-2.09 (m, 2H); 1.99-1.90 (m, 1H); 1.37 (s, 9H). 13C NMR [125 MHz, CDCl3] δ: 176.7, 173.2, 
172.7, 171.86, 165.23, 162.3 (d, J = 246.1 Hz), 154.62, 138.8, 133.8 (d, J = 3.1 Hz), 128.6, 128.1 (d, 
J = 7.9 Hz, 127.7, 127.4, 116.0 (d, J = 21.6 Hz), 80.7, 64.0, 52.3, 52.0, 51.5, 49.0, 47.5, 45.0, 43.7, 
37.7, 32.5, 31.5, 28.3, 23.0, 21.2. MS (ES+) m/z 586.3 (M + 1)+ HPLC 3.01 min (96%) 
(H2O/CH3CN from 15/85 to 0/100 in 5 min flow rate of 1 mL/min). Anal. for C31H41FN4O6 (C, H, F, 






Following the general procedure, a solution of N-cyclohexyl-4-piperidone (0.22 mmol, 39 mg), 4-
fluorobenzylamine (0.44 mmol, 0.066 mL), Boc-Asp(OMe)-OH (0.44 mmol, 122 mg) and benzyl 
isocyanide (0.44 mmol, 0.071 mL) in MeOH (2 mL) was reacted. The final residue was purified to 
give 6 (15 mg, 10%) as a white foam. 1H NMR [400 MHz, CDCl3] δ: 7.21 (m, 9H), 6.91 (t, J = 8.4 
Hz, 2H), 6.73 (s, 1H), 4.95 (d, J = 9.4 Hz, 2H), 4.70 (s, 2H), 4.33 (qd, J = 14.8, 5.8 Hz, 2H), 3.48 (s, 
3H), 2.58 (ddd, J = 75.6, 20.5, 10.5 Hz, 8H), 2.33 (d, J = 12.9 Hz, 2H), 2.12 (s, 2H), 1.86 (s, 2H), 
1.69 (t, J = 12.6 Hz, 5H), 1.52 (d, J = 12.3 Hz, 2H), 1.11 (m, 4H). 13C NMR [100 MHz, CDCl3] δ: 
173.36, 172.60, 171.66, 167.97, 167.62, 163.40, 154.71, 138.8 (d, J = 2.1 Hz), 134.03, 128.67, 
128.13, 127.90, 127.39, 116.1 (d, J = 23 Hz), 115.83, 63.54, 52.00, 47.45, 45.64, 43.75, 29.00, 
28.32, 26.01.MS (ES+) m/z 653.4 (M + 1)+ HPLC 3.29 min (95%) (H2O/CH3CN from 15/85 to 
0/100 in 5 min, flow rate of 1 mL/min). Anal. for C36H49FN4O6 (C, H, F, N): C, 66.24; H, 7.57; F, 
2.91; N, 8.58. Found: C, 66.23; H, 7.60; F, 2.92; N, 8.55. 
4.7. Methyl (S)-4-((4-(benzylcarbamoyl)-1-phenylpiperidin-4-yl)(4-fluorobenzyl)amino)-3-((tert-
butoxycarbonyl)amino)-4-oxobutanoate (7) 
Following the general procedure, a solution of N-phenyl-4-piperidone (37 mg, 0.21 mmol), 4-
fluorobenzylamine (0.43 mmol, 0.066 mL), Boc-Asp(OMe)-OH (120 mg, 0.43 mmol) and benzyl 
isocyanide (0.43 mmol, 0.07 mL) in MeOH (2 mL) was reacted. The final residue was purified to 
give 7 (102 mg, 75%) as an orange oil. 1H NMR [400 MHz, CDCl3] δ: 7.40-7.12 (m, 9H), 6.95 (t, J 
= 8.4 HZ, 2H), 6.85-6.75 (m, 4H), 5.08 (d, J = 9.1 HZ, 1H), 4.89-4.68 (m, 3H), 4.46-4.34 (m, 2H), 
3.52 (s, 3H), 3.51-3.23 (m, 3H), 3.41 (m, 5H), 3.12 (t, J = 11.5 Hz, 1H), 2.85-2.73 (m, 1H), 2.68 (d, J 
= 12.5 Hz, 1H), 2.63-2.52 (m, 1H), 2.41 (d, J = 12.3 Hz, 1H), 2.16-2.05 (m, 1H), 1.98-1.89 (m, 1H), 
1.37 (s, 9H). 13C NMR [100 MHz, CDCl3] δ: 173.3, 172.7, 171.9, 162.3 (d J = 246.0 Hz), 154.8, 
150.9, 138.9, 138.8 (d, J = 3.3 Hz), 129.3, 128.7, 128.2 (d, J = 8.0 Hz), 127.9, 127.5, 119.5, 116.1 (d, 
J = 19Hz), 80.7, 65.1, 52.1, 49.1, 47.8, 46.6, 46.1, 43.8, 37.8, 32.9, 32.1, 28.4. MS (ES+) m/z 647.8 




Anal. for C36H43FN4O6 (C, H, F, N): C, 66.86; H, 6.70; F, 2.94; N, 8.66. Found: C, 66.84; H, 6.72; F, 
2.91; N, 8.68. 
4.8. Methyl (S)-4-((4-(benzylcarbamoyl)-1-phenethylpiperidin-4-yl)(4-fluorobenzyl)amino)-3-((tert-
butoxycarbonyl)amino)-4-oxobutanoate (8) 
Following the general procedure, a solution of N-phenethyl-4-piperidone (0.29 mmol, 58.95 mg), 4-
fluorobenzylamine (0.58 mmol, 0.066 mL), Boc-Asp(OMe)-OH (0.58 mmol, 143 mg) and benzyl 
isocyanide (0.58 mmol, 0.071 mL) in MeOH (2 mL) was reacted. The final residue was purified to 
give 8 (150 mg, 77%) as a white foam. 1H NMR [500 MHz, CDCl3] δ: 7.33 (m, 4H), 7.25 (m, 5H), 
7.16 (m, 3H), 6.99 (t, J = 8.5 Hz, 2H), 6.76 (t, J = 5.8 Hz, 1H), 5.02 (d, J = 9.4 Hz, 1H), 4.78 (s, 2H), 
4.39 (qd, J = 14.8, 5.7 Hz, 2H), 3.54 (s, 3H), 2.76 (dt, J = 26.2, 8.7 Hz, 6H), 2.58 (m, 4H), 2.39 (m, 
2H), 2.02 (m, 1H), 1.86 (s, 2H), 1.37 (s, 9H). 13C NMR [125 MHz, CDCl3] δ: 169.22, 168.53, 
167.62, 158.10 (d, J = 246.0 Hz), 150.59, 136.14, 134.73, 129.83 (d, J = 3.2 Hz), 124.68, 124.66, 
124.65, 124.55, 124.53, 124.49, 124.42, 124.38, 124.06, 123.99, 123.72, 123.28, 122.09, 122.06, 
111.89 (d, J = 21.5 Hz), 76.52, 60.93, 55.99, 47.90, 46.36, 45.82, 45.06, 43.44, 39.61, 33.60, 29.55, 
28.98, 28.18, 25.73, 24.30, 24.23. MS (ES+) m/z 675.5 (M + 1)+ HPLC 5.22 min (97%) 
(H2O/CH3CN from 15/85 to 0/100 in 10 min, flow rate of 1 mL/min). Anal. for C38H47FN4O6 (C, H, 
F, N): C, 67.64; H, 7.02; F, 2.82; N, 8.30. Found: C, 67.63; H, 7.00; F, 2.85; N, 8.32. 
4.9. Methyl (S)-4-((1-benzyl-4-(cyclohexylcarbamoyl)piperidin-4-yl)(4-fluorobenzyl)amino)-3-((tert-
butoxycarbonyl)amino)-4-oxobutanoate (9) 
Following the general procedure, a solution of N-benzyl-4-piperidone (0.33 mmol, 0.061 mL), 4-
fluorobenzylamine (0.66 mmol, 0.075 mL), Boc-Asp(OMe)-OH (0.66 mmol, 163 mg) and cyclo-
hexyl isocyanide (0.66 mmol, 0.082 mL) in MeOH (2 mL) was reacted. The final residue was puri-
fied to give 9 (180 mg, 79%) as a white foam. 1H NMR [500 MHz, (CD3)2SO] δ: 1.09-1.20 (m, 8H), 
1.26 (s, 9H), 1.45 (m, 3H), 1.62 (m, 4H), 1.76 (m, 1H), 2.10 (m, 2H), 2.33 (m, 1H), 2.81 (m, 1H), 
3.27 (m, 2H), 3.24 (m, 1H), 3.44 (s, 3H), 4.65 (m, 3H), 6.82 (d, J = 5.6 Hz, 1H),7.20 (m. 9H), 7.50 
(m, 1H).13C NMR [125 MHz, (CD3)2SO] δ: 171.5, 170.9, 161.3 (d, J = 242.9 Hz), 1550.3, 138.4 (d, 




51.5, 49.9, 49.3, 48.9, 47.5, 46.7, 28.0, 25.3, 24.8. MS (ES+) m/z 653.3 (M + 1)+ HPLC 7.27 min 
(97%) (H2O/CH3CN from 15/85 to 0/100 in 10 min, flow rate of 1 mL/min). Anal. for C36H49FN4O6 
(C, H, F, N): C, 66.24; H, 7.57; F, 2.91; N, 8.58. Found: C, 66.26; H, 7.55; F, 2.89; N, 8.60. 
4.10. Methyl (S)-4-((1-benzyl-4-(tert-butylcarbamoyl)piperidin-4-yl)(4-fluorobenzyl)amino)-3-((tert-
butoxycarbonyl)amino)-4-oxobutanoate (10) 
Following the general procedure, a solution of N-benzyl-4-piperidone (0.33 mmol, 0.061 mL), 4-
fluorobenzylamine (0.66 mmol, 0.075 mL), Boc-Asp(OMe)-OH (0.66 mmol, 163 mg) and tert-
buthyl isocyanide (0.66 mmol, 0.079 mL) in MeOH (2 mL) was reacted. The final residue was puri-
fied to give 10 (161 mg, 74%) as a white foam. 1H NMR [500 MHz, (CD3)2SO] δ: 7.56 (m, 2H9, 
7.40 (d, J = 8.3 Hz, 1H), 7.27 (m, 3H), 7.19 (m, 5H), 6.24 (bs, 1H), 4.79 (d, J = 18.4 Hz, 1H), 4.67 
(cuart., J = 7.3 Hz, 1H), 4.63 (d, J = 18.4 Hz, 1H), 3.58 (s, 3H), 2.85 (dd, J = 16.5, 6.6 Hz), 2.44 (m, 
2H), 2.21 (m, 2H), 2.01 (m, 1H), 1.79 (m, 1H), 1.56 (m, 1H), 1.42 (s, 1H), 1.31 (s, )H), 1.42 (s, 1H), 
1.18 (s, 9H). 13C NMR [125 MHz, (CD3)2SO] δ: 171.58, 171.10, 170.96, 161.29 (d, J = 243.0 Hz), 
155.02, 138.49, 135.19 (d, J = 2.9 Hz), 128.78 (d, J = 7.7 Hz), 128.69, 128.09, 128.04, 126.75, 
115.34 (d, J = 21.3 Hz)78.49, 64.27, 61.80, 51.48, 49.90, 49.73, 49.17, 46.29, 36.05, 28.16, 28.04. 
MS (ES+) m/z 627.6 (M + 1)+ HPLC 7.14 min (98%) (H2O/CH3CN from 15/85 to 0/100 in 10 min, 
flow rate of 1 mL/min). Anal. for C34H47FN4O6 (C, H, F, N): C, 65.16; H, 7.56; F, 3.03; N, 8.94. 
Found: C, 65.19; H, 7.54; F, 3.00; N, 8.90. 
4.11. Methyl (S)-4-((1-benzyl-4-((tosylmethyl)carbamoyl)piperidin-4-yl)(4-fluorobenzyl)amino)-3-
((tert-butoxycarbonyl)amino)-4-oxobutanoate (11) 
Following the general procedure, a solution of N-benzyl-4-piperidone (0.33 mmol, 0.061 mL), 4-
fluorobenzylamine (0.66 mmol, 0.075 mL), Boc-Asp(OMe)-OH (0.66 mmol, 163 mg) and p-
toluenesulfonylmethyl isocyanide (0.66 mmol, 129 mg) in MeOH (2 mL) was reacted. The final 
residue was purified to give 11 (100 mg, 41%) as a white foam. 1H NMR [500 MHz, (CD3)2SO] δ: 
9.03 (m, 1H), 8.06 (bt, J = 5.8 Hz, 1H), 7.73 (d, J = 8.1 Hz, 1H), 7.68 (d, J = 8.1 Hz, 1H), 7.49 (m, 
1H), 7.44 (m, 1H), 7.38 (d, J = 7.1 Hz, 2H), 7.26 (t, J = 7.3 Hz, 2H), 7.18 (m, 3H), 7.11 (d, J = 7.1 




(dd, J = 16.0, 6.9 Hz, 1H), 2.40 (s, 1H), 2.36 (s, 2H), 2.29 (d, J = 10.6 Hz, 1H), 2.22 (d, J = 10.6 Hz, 
1H), 1.94 (m, 2H), 1.81 (m, 1H), 1.52 (m, 1H), 1.43 (m, 1H), 1.21 (s, 9H). 13C NMR [125 MHz, 
(CD3)2SO] δ: 172.16, 171.44, 171.05, 161.60 (d, J = 160.4 Hz), 160.31, 154.68, 144.69, 144.41, 
138.49, 134.75, 134.73 (d, J = 3.5 Hz), 129.80, 129.66, 128.53 (d, J = 6.7 Hz), 128.10, 126.78, 
115.12 (d, J = 21.2 Hz), 78.51, 63.53, 61.55, 60.53, 58.53, 51.43, 49.43, 49.00, 48.93, 46.93, 36.57, 
31.78, 30.92, 27.86, 21.08. MS (ES+) m/z 739.6 (M + 1)+ HPLC 7.14 min (95%) (H2O/CH3CN from 
15/85 to 0/100 in 10 min, flow rate of 1 mL/min). Anal. for C38H47FN4O8S (C, H, F, N): C, 61.77; 
H, 6.41; F, 2.57; N, 7.58. Found: C, 61.75; H, 6.43; F, 2.60; N, 7.55. 
4.12. Methyl (S)-4-((1-benzyl-4-(benzylcarbamoyl)piperidin-4-yl)(4-methylbenzyl)amino)-3-((tert-
butoxycarbonyl)amino)-4-oxobutanoate (17) 
Following the general procedure, a solution of N-benzyl-4-piperidone (0.21 mmol, 0.054 mL), 4-
methylbenzylamine (52 mg, 0.43 mmol), Boc-Asp(OMe)-OH (119 mg, 0.43 mmol) and benzyl iso-
cyanide (0.43 mmol, 0.06 mL) in MeOH (2 mL) was reacted. The final residue was purified to give 
17 (132 mg, 95%) as an orange oil. 1H NMR [400 MHz, CDCl3] δ: 7.40-7.14 (m, 12H), 7.10 (t, J = 
11.0 Hz, 2H), 6.71 (s, 1H), 5.12 (d, J = 9.0 Hz, 1H), 4.87-4.70 (m, 3H), 4.50-4.24 (m, 2H), 3.54 (s, 
3H), 3.47-3.37 (m, 2H), 2.74 (m, 1H), 2.69-2.61 (m, 2H), 2.60-2.44 (m, 3H), 2.37 (m, 1H), 2.30 (s, 
3H), 2.16 (m, 1H), 1.99 (m, 1H), 1.86 (m, 1H), 1.38 (s, 9H). 13C NMR [100 MHz, CDCl3] δ: 173.2, 
172.9, 171.7, 154.8, 139.0, 138.7, 137.2, 135.2, 129.8, 129.3, 128.7, 128.4, 128.0, 127.4, 127.2, 
126.5, 80.5, 65.3, 62.9, 52.0, 50.7, 50.1, 49.3, 48.1, 43.8, 37.8, 33.2, 32.5, 28.4, 21.3. MS (ES+) m/z 
657.3 (M + 1)+ HPLC 8.69 min (98%) (H2O/CH3CN from 15/85 to 0/100 in 10 min, flow rate of 1 




Following the general procedure, a solution of N-benzyl-4-piperidone (0.12 mmol, 0.025 mL), 4-
(trifluoromethyl)benzylamine (0.24 mmol, 0.035 mL), Boc-Asp(OMe)-OH -OH (66.7 mg, 0.24 




was purified to give 18 (81 mg, 95%) as a white foam. 1H NMR [400 MHz, CDCl3] δ: 7.59 (d, J = 
8.2 Hz, 2H), 7.53 (d, J = 8.2 Hz, 2H), 7.39-7.21 (m, 10H), 6.82 (t, J = 4.5 Hz, 1H), 5.03 (d, J = 9.4 
Hz, 1H), 4.88 (s, 2H), 4.71 (m, 1H), 4.52-4.37 (m, 2H), 3.57 (s, 3H), 3.40 (s, 2H), 2.80 (dd, J = 16.5 
Hz, J = 8.6 Hz, 1H), 2.67 (m, 2H), 2.65-2.46 (m, 4H), 2.46-2.25 (m, 1H), 2.01-1.89 (m, 2H), 1.80 
(m, 1H), 1.37 (s, 9H). 13C NMR [100 MHz, CDCl3] δ: 173.5, 172.5, 171.8, 154.7, 142.6, 138.8, 
138.4, 129.31, 128.8, 128.4, 127.9, 127.5, 127.2, 126.8, 126.1 (d, J = 3.6 Hz), 80.8, 65.39, 62.9, 
52.1, 50.6, 50.1, 49.2, 48.0, 43.9, 37.7, 33.2, 32.63, 28.3. MS (ES+) m/z 711.5 (M + 1)+ HPLC 3.52 
min (99%) (H2O/CH3CN from 15/85 to 0/100 in 5 min, then isocratic for 2 min; flow rate of 1 
mL/min). Anal. for C38H45F3N4O6 (C, H, F, N): C, 64.21; H, 6.38; F, 8.02; N, 7.88. Found: C, 64.19; 
H, 6.41; F, 8.00; N, 7.87. 
4.14. Methyl (S)-4-((1-benzyl-4-(benzylcarbamoyl)piperidin-4-yl)(4-nitrobenzyl)amino)-3-((tert-
butoxycarbonyl)amino)-4-oxobutanoate (19) 
Following the general procedure, a solution of N-benzyl-4-piperidone (0.21 mmol, 0.025 mL), 4-
nitrobenzylamine (66 mg, 0.43 mmol), Boc-Asp(OMe)-OH (119 mg, 0.43 mmol) and benzyl isocy-
anide (0.43 mmol, 0.054 mL) in MeOH (2 mL) was reacted. The final residue was purified to give 
19 (124 mg, 86%) as a colourless oil. 1H NMR [400 MHz, CDCl3] δ: 8.18 (d, J = 8.6 Hz, 2H), 7.59 
(d, J = 8.4 Hz, 2H), 7.41-7.15 (m, 10Hz), 6.84 (s, 1H), 5.02-4.79 (m, 2H), 4.63 (d, J = 4.0 Hz, 1H), 
4.42 (d, J = 5.8 Hz, 2H), 3.56 (s, 3H), 3.41 (s, 2H), 2.8 (m, 1H), 2.67 (m, 2H), 2.55 (m, 2H), 2.43 (m, 
2H), 2.28 (t, J = 11.5 Hz, 1H), 1.92 (m, 1H), 1.79 (m, 1H), 1.34 (s, 9H).13C NMR [100 MHz, CDCl3] 
δ: 173.6, 172.2, 171.8, 154.6, 147.5, 146.0, 138.7, 138.3, 129.3, 128.8, 127.9, 127.6, 127.4, 127.3, 
124.3, 80.9, 65.4, 62.9, 52.2, 50.6, 50.5, 50.1, 49.3, 47.9, 43.9, 37.7, 33.2, 32.7, 28.3.MS (ES+) m/z 
688.5 (M + 1)+ HPLC 8.91 min (97%) (H2O/CH3CN from 15/85 to 0/100 in 10 min, flow rate of 1 







Following the general procedure, a solution of N-benzyl-4-piperidone (0.12 mmol, 0.025 mL), 4-
chlorobenzylamine (34 mg, 0.24 mmol), Boc-Asp(OMe)-OH -OH (67 mg, 0.24 mmol) and benzyl 
isocyanide (0.24 mmol, 0.03 mL) in MeOH (2 mL) was reacted. The final residue was purified to 
give 20 (70 mg, 86%) as a colourless oil. 1H NMR [400 MHz, CDCl3] δ: 7.49-7.09 (m, 14H), 6.74 
(t, J = 5.0 Hz), 5.02 (d, J = 9.3 Hz, 1H), 4.75 (s, 2H), 4.73-4.66 (m, 1H), 4.45-4.32 (m, 2H), 3.52 (s, 
3H), 3.47-3.34 (m, 2H), 2.75 (m, 1H), 2.69-2.60 (m, 2H), 2.54 (m, 3H, 2), 2.32 (m, 2H), 1.91 (m, 
1H), 1.86-1.73 (m, 1H), 1.35 (s, 9H). 13C NMR [100 MHz, CDCl3] δ: 173.3, 172.5, 171.6, 154.5, 
138.7, 138.4, 136.8, 133.3, 129.2, 129.1, 128.6, 128.3, 127.8, 127.8, 127.3, 127.1, 80.6, 65.2, 62.8, 
52.0, 50.5, 49.9, 49.1, 47.6, 43.7, 37.6, 33.1, 32.4, 29.8, 28.3. MS (ES+) m/z 677.6 (M + 1)+ HPLC 
3.42 min (98%) (H2O/CH3CN from 15/85 to 0/100 in 5 min, flow rate of 1 mL/min). Anal. for 
C37H45ClN4O6 (C, H, N).C, 65.62; H, 6.70; N, 8.27. Found: C, 65.64; H, 6.69; N, 8.30. 
4.16. Methyl (S)-4-((1-benzyl-4-(benzylcarbamoyl)piperidin-4-yl)(2-fluorobenzyl)amino)-3-((tert-
butoxycarbonyl)amino)-4-oxobutanoate (21) 
Following the general procedure, a solution of N-benzyl-4-piperidone (0.29 mmol, 0.054 mL), 2-
fluorobenzylamine (0.58 mmol, 0.066 mL), Boc-Asp(OMe)-OH (0.58 mmol, 143 mg) and benzyl 
isocyanide (0.58 mmol, 0.071 mL) in MeOH (2 mL) was reacted. The final residue was purified to 
give 21 (182 mg, 95%) as a white foam.1H NMR [500 MHz, (CD3)2SO] δ: .92 (bt, J = 5.9 Hz, 1H), 
7.70 (m, 1H), 7.23 (m, 12 H), 7.12 (m, 2H), 4.90 (d, J = 19.0 Hz, 1H), 4.66 (m, 2H), 4.23 (d, J = 5.9 
Hz, 2H), 3.52 (s, 3H), 3.35 (s, 3H), 3.27 (s, 2H), 2.79 (dd, J = 16.3, 6.0 Hz, 1H), 2.47 (m, 2H), 2.22 
(m, 2H), 1.67 (td, J = 12.2, 4.2 Hz, 1H), 1.50 (m, 1H), 1.23 (s, 9H).13C NMR [125 MHz, (CD3)2SO] 
δ: 172.14, 171.70, 170.90, 170.37, 159.07 (d, J = 243.8 Hz), 154.93, 140.04, 138.42, 129.07 (d, J = 
3.4 Hz), 128.97 (d, J = 8.2 Hz), 128.69, 128.36, 128.12, 127.08, 126.81, 126.48, 125.62 (d, J = 13.2 
Hz), 124.40 (d, J = 3.4 Hz), 115.26 (d, J = 21.3 Hz), 78.44, 63.54, 61.66, 59.80, 51.52, 49.70, 49.47, 
49.13, 42.35, 36.44, 31.82, 27.94, 20.80, 14.12.MS (ES+) m/z 661.5 (M + 1)+ HPLC 7.15 min (97%) 
(H2O/CH3CN from 15/85 to 0/100 in 10 min, flow rate of 1 mL/min). Anal. for C37H45FN4O6 (C, H, 






Following the general procedure, a solution of N-benzyl-4-piperidone (0.29 mmol, 0.054 mL), 3-
fluorobenzylamine (0.58 mmol, 0.066 mL), Boc-Asp(OMe)-OH (0.58 mmol, 143 mg) and benzyl 
isocyanide (0.58 mmol, 0.071 mL) in MeOH (2 mL) was reacted. The final residue was purified to 
give 22 (163 mg, 85%) as a white foam. 1H NMR [500 MHz, (CD3)2SO] δ: 7.81 (t, J = 6.0 Hz, 1H), 
7.52 (dd, J = 8.5, 5.4 Hz, 2H), 7.22 (m, 12H), 4.70 (m, 3H), 4.22 (dd, J = 5.7, 2.7 Hz, 2H), 3.52 (s, 
3H), 3.34 (s, 2H), 3.27 (s, 2H), 2.79 (dd, J = 16.3, 6.0 Hz, 1H), 2.18 (m, 2H), 1.75 (dt, J = 12.8, 6.7 
Hz, 1H), 1.51 (m, 1H), 1.25 (s, 9H). 13C NMR [125 MHz, (CD3)2SO] δ: 172.30, 171.50, 170.96, 
161.29 (d, J = 242.7 Hz), 154.95, 140.05, 138.44, 134.95 (d, J = 2.9 Hz)128.82, 128.76, 128.70, 
128.36, 128.11, 127.32, 127.05, 126.64 (d, J = 41.4 Hz), 115.20 (d, J = 21.2 Hz), 78.42, 63.74, 
61.66, 51.53, 49.68, 49.46, 49.07, 46.93, 42.31, 36.37, 31.96, 31.88, 27.98, 27.64, 20.81, 14.12. MS 
(ES+) m/z 661.9 (M + 1)+ HPLC 8.32 min (98%) (H2O/CH3CN from 15/85 to 0/100 in 10 minflow 
rate of 1 mL/min). Anal. for C37H45FN4O6 (C, H, F, N). C, 67.25; H, 6.86; F, 2.88; N, 8.48. Found: 
C, 67.22; H, 6.89; F, 2.85; N, 8.50 
4.18. Methyl (S)-4-((1-benzyl-4-(benzylcarbamoyl)piperidin-4-yl)(3,4-difluorobenzyl)amino)-3-
((tert-butoxycarbonyl)amino)-4-oxobutanoate (23) 
Following the general procedure, a solution of N-benzyl-4-piperidone (0.29 mmol, 0.054 mL), 3,4-
difluorobenzylamine (0.58 mmol, 0.069 mL), Boc-Asp(OMe)-OH (0.58 mmol, 143 mg) and benzyl 
isocyanide (0.58 mmol, 0.071 mL) in MeOH (2 mL) was reacted. The final residue was purified to 
give 23 (178 mg, 90%) as a white foam. 1H NMR [500 MHz, (CD3)2SO] δ: 7.86 (t, J = 6.0 Hz, 1H), 
7.64 (m, 1H), 7.40 (m, 2H), 7.22 (m, 11H), 4.68 (m, 3H), 4.22 (t, J = 6.8 Hz, 2H), 3.52 (s, 3H), 3.33 
(s, 1H), 3.29 (s, 2H), 2.78 (dd, J = 16.3, 6.2 Hz, 1H), 2.44 (m, 3H), 2.18 (q, J = 11.6 Hz, 2H), 1.74 
(td, J = 12.6, 4.2 Hz, 1H), 1.51 (d, J = 11.0 Hz, 1H), 1.23 (s, 9H). 13C NMR [125 MHz, (CD3)2SO] δ: 
172.67, 171.99, 171.36, 161.46, 155.34, 150.36 (dd, J = 126.8, 12.4 Hz), 148.41 (dd, J = 126.0, 12.5 
Hz), 140.44, 138.83, 137.31 (m), 129.11, 128.77, 128.54, 128.52, 127.72, 127.47, 127.32, 127.24, 




51.94, 50.12, 49.83, 49.47, 47.09, 42.76, 36.76, 32.40, 32.34, 28.34, 28.00, 21.22, 14.53.MS (ES+) 
m/z 679.9 (M + 1)+ HPLC 9.01 min (97%) (H2O/CH3CN from 15/85 to 0/100 in 10 min, flow rate of 
1 mL/min). Anal. for C37H44F2N4O6 (C, H, F, N): C, 65.47; H, 6.53; F, 5.60; N, 8.25. Found: C, 
65.50; H, 6.51; F, 5.58; N, 8.28. 
4.19. Methyl (S)-4-((1-benzyl-4-(benzylcarbamoyl)piperidin-4-yl)(4-fluorobenzyl)amino)-4-
oxobutanoate (25) 
Following the general procedure, a solution of N-benzyl-4-piperidone (0.21 mmol, 0.054 mL), 4-
fluorobenzylamine (0.58 mmol, 0.066 mL), mono-methyl hydrogen succinate (77 mg, 0.58 mmol) 
and benzyl isocyanide (0.58 mmol, 0.071 mL) in MeOH (2 mL) was reacted. The final residue was 
purified to give 25 (111 mg, 97%) as a colourless oil. 1H NMR [500 MHz, CDCl3] δ: 7.36-7.20 (m, 
12H); 7.05-6.99 (m, 2H); 6.91 (ta, J = 5.2 Hz, 1H); 4.65 (s, 2H); 4.42 (d, J = 5.7 Hz, 2H); 3.63 (s, 
3H); 3.41 (s, 2H); 2.72-2.6 (m, 4H); 2.61-2.50 (m, 4H); 2.32 (t, J = 11.2 Hz, 2H); 1.87 (m, 2H). 13C 
NMR [125 MHz, CDCl3] δ: 7.36-7.20 (m, 12H); 7.05-6.99 (m, 2H); 6.91 (ta, J = 5.2 Hz, 1H); 4.65 
(s, 2H); 4.42 (d, J = 5.7 Hz, 2H); 3.63 (s, 3H); 3.41 (s, 2H); 2.72-2.6 (m, 4H); 2.61-2.50 (m, 4H); 
2.32 (t, J = 11.2 Hz, 2H); 1.87 (m, 2H). MS (ES+) m/z 546.3 (M + 1)+ HPLC 2.97 min (95%) 
(H2O/CH3CN from 15/85 to 0/100 in 5 min, flow rate of 1 mL/min). Anal. for C32H36FN3O4 (C, H, 
F, N): C, 70.44; H, 6.65; F, 3.48; N, 7.70. Found: C, 70.49; H, 6.66; F, 3.47; N, 7.69. 
4.20. Methyl (S)-4-((1-benzyl-4-(benzylcarbamoyl)piperidin-4-yl)-4-fluorobenzyl)amino)-3-
benzyloxycarbonylamino-4-oxobutanoate (26) 
Following the general procedure, a solution of N-benzyl-4-piperidone (0.87 mmol, 0.16 mL), 4-
fluorobenzylamine (1.75 mmol, 0.2 mL), Cbz-Asp(OMe)-OH (1.75 mmol, 492 mg) and benzyl iso-
cyanide (1.75 mmol, 0.21 mL) in MeOH (2 mL) was reacted. The final residue was purified to give 
26 (548 mg, 90%) as a white foam.1H NMR (500 MHz, DMSO-d6) δ 7.84 (m, 2H), 7.56 (dd, J = 8.4, 
5.3 Hz, 2H), 7.39 – 7.12 (m, 15H), 5.75 (s, 1H), 5.00 (d, J = 12.5 Hz, 1H), 4.91 (d, J = 12.5 Hz, 1H), 
4.83 – 4.65 (m, 3H), 4.24 (d, J = 5.7 Hz, 2H), 3.55 (s, 3H), 3.33 (m, 2H), 2.89 (dd, J = 16.7, 5.2 Hz, 
1H), 2.60 – 2.52 (m, 2H), 2.22 (m, 2H), 1.79 (td, J = 12.8, 4.2 Hz, 1H), 1.50 (m, 1H). 13C NMR (126 




134.7, 128.8, 128.74 (d, J = 7.9 Hz), 128.3, 128.1, 128.0, 127.8, 127.7, 127.0, 126.7, 126.5, 115.25 
(d, J = 21.3 Hz), 65.7, 63.7, 61.6, 54.9, 51.6, 49.9, 49.7, 48.9, 46.8, 42.3, 36.0, 32.1, 31.8. MS (ES+) 
m/z 696.2 (M + 1)+ HPLC 7.09 min (98%) (H2O/CH3CN from 10/90 to 0/100 in 10 min, then iso-
cratic for 2 min; flow rate of 1 mL/min). Anal. for C40H43FN4O6 (C, H, F, N): C, 69.15; H, 6.24; F, 
2.73; N, 8.06. Found: C, 69.17; H, 6.22; F, 2.70; N, 8.09. 
4.21. tert-Butyl (S)-(1-((1-benzyl-4-(benzylcarbamoyl)piperidin-4-yl)(4-fluorobenzyl)amino)-1-
oxopropan-2-yl)carbamate (27) 
Following the general procedure, a solution of N-benzyl-4-piperidone (0.21 mmol, 0.054 mL), 4-
fluorobenzylamine (0.58 mmol, 0.066 mL), Boc-Ala(OMe)-OH (118 mg, 0.58 mmol) and benzyl 
isocyanide (0.58 mmol, 0.071 mL) in MeOH (2 mL) was reacted. The final residue was purified to 
give 27 (126 mg, 97%) as a colourless oil.1H NMR [500 MHz, CDCl3] δ: 7.33-7.10 (m, 1H); 6.97-
6.80 (m, 3H, 11); 5.07 (d, J = 7.0 Hz, 1H); 4.74 (d, J = 18,2 HZ, 1H); 4.51 (d, J = 18.2 Hz, 1H); 4.32 
(m, 3H); 3.33 (d, J = 13.2 Hz, 2H); 2.59 (m, 3H; 2); 2.34 (m, 2H); 2.23 (m, 1H); 1.85 (m, 2H); 1.38 
(s, 9H); 1.08 (d, J = 6.6 Hz, 3H). 13C NMR [125 MHz, CDCl3] δ: 175.3, 171.0 , 161.0 (d, J = 246.2 
Hz), 154.1 (28), 137.4, 137.1, 132.7 (d, J = 1.9 Hz), 128.1, 127.5, 127.2, 126.8 (d, J = 7.6 Hz), 
126.7, 126.2, 126.0, 114.8 (d, J = 21.6 Hz), 78.8, 64.03, 61.71, 49.4, 49.1, 47.2, 46.3, 42.6, 31.8, 
31.7, 27.6, 18.0. MS (ES+) m/z 603.5 (M + 1)+ HPLC 3.31 min (99%) (H2O/CH3CN from 15/85 to 
0/100 in 5 min, flow rate of 1 mL/min). Anal. for C35H43FN4O4 (C, H, F, N): C, 69.74; H, 7.19; F, 
3.15; N, 9.30. Found: C, 69.77; H, 7.21; F, 3.13; N, 9.28. 
4.22. Methyl (S)-5-((1-benzyl-4-(benzylcarbamoyl)piperidin-4-yl)(4-fluorobenzyl)amino)-4-((tert-
butoxycarbonyl)amino)-5-oxopentanoate (28) 
Following the general procedure, a solution of N-benzyl-4-piperidone (0.21 mmol, 0.054 mL), 4-
fluorobenzylamine (0.48 mmol, 0.066 mL), Boc-Glu(OMe)-OH (0.48 mmol) and benzyl isocyanide 
(0.42 mmol, 0.071 mL) in MeOH (2 mL) was reacted. The final residue was purified to give 28 (72 
mg, 50%) as a white foam. 1H NMR [500 MHz, CDCl3] δ: 8.07-7.82 (m, 4H), 7.43-7.13 (m, 7H), 
6.97 (t, J = 8.2 Hz, 2H), 6.76 (bs, 1H), 5.16 (d, J = 8.0 Hz, 1H), 4.76 (m, 2H), 4.54-4.29 (m, 3H, 12), 




1.46-1.29 (m, 9H). 13C NMR [125 MHz, CDCl3] δ: 175.0, 173.2, 172.1, 162.6, 162.1 (d, J = 246.3 
Hz), 155.53, 138.5, 138.2, 133.7, 129.2, 128.7, 128.3, 128.1 (d, J = 8.1 Hz), 128.0, 127.4, 127.1, 
115.94 (d, J = 21.6 Hz), 80.0, 65.2, 62.8, 51.8, 51.8, 50.43, 50.2, 47.23, 43.8, 33.0, 28.64, 28.3. MS 
(ES+) m/z 675.6 (M + 1)+ HPLC 3.31 min (96%) (H2O/CH3CN from 85/15 to 5/95 in 5 min, flow 
rate of 1 mL/min). Anal. for C38H47FN4O6 (C, H, F, N): C, 67.64; H, 7.02; F, 2.82; N, 8.30. Found: 
C, 67.61; H, 6.99; F, 2.85; N, 8.28. 
4.23. tert-Butyl (S)-(1-((1-benzyl-4-(benzylcarbamoyl)piperidin-4-yl)(4-fluorobenzyl)amino)-1-oxo-
3-phenylpropan-2-yl)carbamate (29) 
Following the general procedure, a solution of N-benzyl-4-piperidone (0.22 mmol, 0.054 mL), 4-
fluorobenzylamine (0.44 mmol, 0.066 mL), Boc-Phe-OH (0.44 mmol, 117 mg) and benzyl isocya-
nide (0.44 mmol, 0.071 mL) in MeOH (2 mL) was reacted. The final residue was purified to give 29 
(123 mg, 82%) as a colourless oil. 1H NMR [500 MHz, CDCl3] δ: 7.36 (dd, J = 8.4, 6.6 Hz, 4H), 
7.26 (m, 6H), 7.01 (m, 5H), 6.89 (t, J = 8.3 Hz, 2H), 6.82 (s, 2H), 5.03 (d, J = 8.6 Hz, 1H), 4.45 (d, J 
= 5.7 Hz, 2H), 3.40 (t, J = 12.7 Hz, 2H), 2.99 (dd, J = 13.4, 8.0 Hz, 1H), 2.79 (d, J = 13.4 Hz, 1H), 
2.75 (t, J = 6.1 Hz, 2H), 2.66 (m, 2H), 2.46 (t, J = 6.1 Hz, 2H), 2.25 (m, 2H), 1.77 (td, J = 13.0, 12.2, 
4.8 Hz, 2H), 1.39 (s, 9H), 1.08 (s, 2H).13C NMR [125 MHz, CDCl3] δ: 209.31, 174.72, 171.85, 
162.95, 161.98 (d, J = 246.0 Hz), 154.92, 138.57, 138.21, 138.15, 136.32, 133.79 (d, J = 2.9 Hz), 
129.59, 129.21, 128.96, 128.67 (d, J = 3.9 Hz), 128.44, 128.26, 127.86, 127.69, 127.63, 127.41, 
127.37, 127.34, 127.12, 127.08, 115.88 (d, J = 21.6 Hz), 80.10, 65.27, 62.84, 62.03, 54.04, 52.98, 
50.62, 50.11, 47.08, 43.78, 41.37, 39.93, 32.86, 32.64, 28.33, 27.87. MS (ES+) m/z 679.2 (M + 1)+ 
HPLC 3.62 min (96%) (H2O/CH3CN from 15/85 to 0/100 in 5 min, flow rate of 1 mL/min). Anal. 




Following the general procedure, a solution of N-benzyl-4-piperidone (0.21 mmol, 0.054 mL), 4-




mmol, 0.071 mL) in MeOH (2 mL) was reacted. The final residue was purified to give 31 (119 mg, 
88%) as a white foam. 1H NMR [500 MHz, CDCl3] δ: 7.39 (s, 2H), 7.35-7.15 (m, 10H), 7.00 (t, J = 
8.5 Hz, 2H), 6.66 (m, 2H), 5.94 (bs, 1H), 5.52 (bs, 1H), 4.96 (m, 2H), 4.75 (d, J = 17.8 Hz, 1H), 4.40 
(m, 1H), 4.23 (m, 1H), 3.46 (m, 2H), 2.78 (m, 1H), 2.58 (m, 4H), 2.40 (m, 2H), 2.13 (m, 1H), 1.91-
1.76 (m, 2H), 1.39 (s, 9H).13C NMR [125 MHz,CDCl3] δ: 173.9, 173.7, 172.6, 162.11 (d, J = 246.3 
Hz), 155.1, 138.6, 138.1, 133.9, 129.1, 128.6, 128.4, 128.3, 127.7, 127.3, 127.1, 115.9 (d, J = 21.5 
Hz), 80.3, 64.9, 62.6. MS (ES+) m/z 646.8 (M + 1)+ HPLC 3.02 min (99%) (H2O/CH3CN from 
15/85 to 0/100 in 5 min, flow rate of 1 mL/min). Anal. for C36H44FN5O5 (C, H, F, N): C, 66.96; H, 
6.87; F, 2.94; N, 10.85. Found: C, 66.99; H, 6.85; F, 2.91; N, 10.83. 
4.25. Methyl (S)-4-((4-(benzylcarbamoyl)-1-(3-fluorobenzyl)piperidin-4-yl)(4-fluorobenzyl)amino)-
3-((tert-butoxycarbonyl)amino-4-oxobutanoate (38) 
Following the general procedure, a solution of N-(3-fluorobenzyl)-4-piperidone (0.6 mmol, 125 mg), 
4-fluorobenzylamine (1.2 mmol, 0.137 mL), Boc-Asp(OMe)-OH (1.2 mmol, 297 mg) and benzyl 
isocyanide (1.2 mmol, 0.146 mL) in MeOH (2 mL) was reacted. The final residue was purified to 
give 38 (350 mg, 86%) as a white foam 1H NMR (400 MHz, DMSO-d6) δ 7.79 (d, J = 7.7 Hz, 1H), 
7.54 (dd, J = 8.5, 5.4 Hz, 2H), 7.34 – 7.15 (m, 10H), 7.06 – 6.92 (m, 3H), 4.72 (dd, J = 22.3, 7.2 Hz, 
3H), 4.24 (d, J = 5.5 Hz, 2H), 3.55 (s, 3H), 3.32 (s, 2H), 2.80 (dd, J = 16.3, 6.0 Hz, 1H), 2.48 – 2.39 
(m, 3H), 2.29 – 2.15 (m, 4H), 1.79 (t, J = 13.4 Hz, 1H), 1.60 – 1.52 (m, 1H), 1.27 (s, 9H).13C NMR 
(101 MHz, DMSO) δ 172.7, 172.0, 171.4, 170.7, 162.4 (d, J = 243.1 Hz), 161.7 (d, J = 242.9 Hz), 
155.4, 142.12 (d, J = 7.0 Hz), 140.4, 135.4, 130.40 (d, J = 8.3 Hz), 129.5 (d, J = 7.6 Hz),128.5, 
127.5, 126.9, 124.9, 115.6 (d, J = 21.2 Hz), 115.4 (d, J = 21.0 Hz), 113.9(d, J = 21.0 Hz), 78.9, 64.2, 
61.3, 60.2, 51.9, 50.1, 49.9, 49.5, 47.4, 42.8, 36.8, 32.4, 32.3, 28.4, 21.2, 14.5.MS (ES+) m/z 
679.3(M + 1)+ HPLC 6.78 min (99%) (H2O/CH3CN from 90/10 to 5/95 in 10 min flow rate of 1 
mL/min). Anal. for C37H44F2N4O6 (C, H, F, N): C, 65.47; H, 6.53; F, 5.60; N, 8.25. Found: C, 65.45; 






Following the general procedure, a solution of N-(3,5-difluorobenzyl)-4-piperidone (0.6 mmol, 135 
mg), 4-fluorobenzylamine (1.2 mmol, 0.137 mL), Boc-Asp(OMe)-OH (1.2 mmol, 297 mg) and ben-
zyl isocyanide (1.2 mmol, 0.146 mL) in MeOH (2 mL) was reacted. The final residue was purified to 
give 39 (344 mg, 82%) as a white foam. 1H NMR (400 MHz, DMSO-d6) δ 7.80 (t, J = 5.3 Hz, 1H), 
7.57 – 7.50 (m, 1H), 7.34 – 7.14 (m, 9H), 7.05 (ddd, J = 11.6, 5.8, 2.3 Hz, 1H), 6.86 (d, J = 6.6 Hz, 
2H),4.72 (m, 3H), 4.23 (d, J = 5.6 Hz, 2H), 3.55 (s, 3H), 3.35 (s, 2H), 3.32 (s, 2H), 2.80 (dd, J = 
16.3, 6.0 Hz, 1H), 2.44 (m, 3H), 2.23 (m, 2H), 1.81 (m, 1H), 1.56 (m, 1H), 1.27 (s, 9H). 13C NMR 
(101 MHz, DMSO-d6) δ 172.7, 171.9, 171.4, 170.8, 162.7 (d, J = 245.1 Hz), 163.0 (d, J = 245.2 Hz), 
161.8 (d, J = 240.3 Hz), 155.4, 144.1 (t, J = 8.6 Hz), 144.0, 135.4, 129.3, 128.5, 127.5, 126.9, 115.58 
(d, J = 21.2 Hz), 111.56 (d, J = 24.6 Hz), 102.58 (t, J = 25.9 Hz), 78.9, 64.1, 60.8, 60.2, 51.9, 50.0, 
49.9, 49.4, 47.4, 42.8, 36.8, 32.4, 32.3, 28.4, 21.1, 14.5. MS (ES+) m/z 697.2 (M + 1)+ HPLC 6.92 
min (99%) (H2O/CH3CN from 90/10 to 5/95 in 10 min; flow rate of 1 mL/min). Anal. for 
C37H43F3N4O66 (C, H, F, N): C, 63.78; H, 6.22; F, 8.18; N, 8.04. Found: C, 63.79; H, 6.20; F, 8.21; 
N, 8.01. 
4.27. Potentiometric pKa determination 
Titrations were carried out at 25 ± 0.5 °C in 0.15 M aqueous KCl solution under a nitrogen atmos-
phere using a SiriusT3 apparatus (Sirius Analytical Instruments Ltd, East Sussex, UK) equipped 
with an Ag/AgCl double junction reference pH electrode and a turbidity sensor. Standardised 0.5 M 
KOH and 0.5 M HCl were used as titration reagents. The KOH solution was standardized by potas-
sium acid phthalate. The pKa values are the mean of 3 titrations ± SD except otherwise noted. 
4.28. Chemical stability 
A solution of 2 (0.6 mg) and 34 (0.6 mg) in acetonitrile: acetate buffer (2 mL, pH=5.5) were incubed 
at 37 ºC for 72 h. The compounds were very stable and no degradation products were observed by 
HPLC and HPLC-MS in these acidic buffered solutions that may mimic the pH conditions at the 
endosomes. 




Virus strains. The panel of influenza virus strains included A/PR/8/34 (A/H1N1; ATCC® VR-95), 
A/Virginia/ATCC3/2009 (H1N1; ATCC® VR-1738), A/HK/7/87 (A/H3N2; a kind gift from J. 
Neyts, Leuven, Belgium), and and B/HK/5/72 (ATCC® VR-823). These viruses were expanded by 
intra-allantoic inoculation in embryonated hen eggs.  
Antiviral procedures based on reduction of virus-induced cytopathic effect. We previously reported 
[33] the cytopathic effect (CPE) reduction assay in influenza virus-infected Madin-Darby canine 
kidney cells (MDCK; kindly donated by M. Matrosovich, Marburg, Germany). Briefly, subconfluent 
cultures of MDCK cells in 96-well plates were infected with virus at an MOI of 50 CCID50 (50% 
cell culture infective dose) per well, and at the same time the test compounds were added in serial 
dilutions. The infection medium consisted of UltraMDCK medium (Lonza), supplemented with 225 
mg/L sodium bicarbonate, 2 mM L-glutamine, and 2 µg/ml TPCK (tosylphenylalanylchloromethyl-
keton)-treated trypsin (Sigma-Aldrich). After 72 h incubation at 35 °C, microscopy was performed 
to score virus-induced CPE and compound cytotoxicity. The results were verified by a colorimetric 
cell viability assay. The MTS cell viability reagent (CellTiter 96® AQueous MTS Reagent from 
Promega) was added to the wells, and 4 h later, absorbance at 490 nm was measured in a plate read-
er.  
The antiviral activity of compounds was expressed as EC50 or concentration showing 50% effective-
ness in the microscopic CPE reduction or MTS assay [see reference 45 for calculation details]. Cyto-
toxicity was expressed as the CC50 or 50% cytotoxic concentration in the MTS assay, and MCC 
(minimum cytotoxic concentration) or concentration producing minimal changes in cell morphology, 
assessed by microscopy. 
Selection of resistant influenza virus mutants. MDCK cells were infected with A/PR/8/34 virus as 
above, and exposed to different concentrations of compound 2. After 72 h, microscopy was done to 
select the highest compound concentrations manifesting some virus-induced CPE, and from these 
wells the cells combined with supernatants were frozen at -80°C. These harvests were further pas-
saged in MDCK cells under gradually increasing compound concentrations until resistance was ob-




parallel. Individual virus clones were obtained by plaque purification under 0.8% agar and 10 µM of 
2, followed by virus expansion in MDCK cells. After RNA extraction and reverse transcription fol-
lowed by high-fidelity PCR, cycle sequencing was done on the HA gene. 
Mechanistic influenza virus assays. For the one-cycle time-of-addition assay described in full detail 
elsewhere [28], MDCK cells were infected with influenza A/PR/8/34 virus and compounds were 
added at -0.5, 0, 0.5, 1, 3, 5 or 8 h p.i. At 10 h p.i., cellular RNA extracts were prepared. vRNA copy 
number (for the M-gene) was determined by two-step RT-qPCR using reported primers and probe 
[33]. The virus binding assay at 4°C was performed [28] using MDCK cells and two-step RT-qPCR 
quantification of cell-bound virus. 
To perform the polykaryon assay [33], the coding sequence for A/PR/8/34 HA was cloned into a 
pCAGEN plasmid [46]. Specific HA mutations were introduced by site-directed mutagenesis and 
verified by cycle sequencing. Plasmid transfection into HeLa cells was carried out in 12-well plates 
as described [13, 33]. Two days later, surface-exposed HA0 was first activated for 15 min with 
TPCK-treated trypsin. Next, the cells were preincubated for 15 min with test compound; exposed for 
5 min to pH 5.2 buffer [i.e. PBS with Ca2+ and Mg2+ (PBS-CM) adapted to pH 5.2 with acetic acid] 
with further presence of compound; and then washed with PBS-CM. Cell culture medium was added 
and after 3 h incubation, the cells were fixated and stained with Giemsa solution to allow microscop-
ic counting of the polykaryons.  
To measure the hemolysis pH of wild-type or mutant virus [33], virus was added to microcentrifuge 
tubes together with an equal volume of 2% chicken red blood cell (RBC) suspension. After 10 min 
incubation at 37 °C, unbound virus was removed by centrifugation. Next, the cell pellets were resus-
pended in acidic buffer, i.e. PBS-CM that was acidified with acetic acid to a pH ranging from 4.6 to 
6 with 0.1 increments. After 25 min incubation, the suspensions were neutralized with NaOH and 
intact RBC were removed by centrifugation. The extent of hemolysis in the supernatants was quanti-
fied by measuring the absorbance at 540 nm using a plate reader. The hemolysis pH was defined as 




Enzymatic assays with diverse proteases. The effect of the synthesized compounds and two refer-
ence molecules, i.e. the broad cathepsin inhibitor E64 and broad serine protease inhibitor camostat, 
was measured in a FRET assay with 7-amino-4-methylcoumarin (AMC) fluorogenic substrates. The 
panel of proteases contained: trypsin (from human pancreas; Athens Research & Technology), hu-
man airway trypsin-like protease (HAT; R&D systems), and cathepsin B, cathepsin F and cathepsin 
L (all from Enzo Life Sciences). The assay buffers contained: for trypsin, 100 mM Tris pH 9 and 5 
mg per ml bovine serum albumin; for HAT: 50 mM Tris pH 9 and 0.05% Brij-35; and for cathepsin 
B, F and L: 50 mM sodium acetate pH 5.5, 2.5 mM EDTA, 0.01% nia. Black 96-well plates contain-
ing serial compound dilutions were installed in a plate reader at 37 °C, and pre-incubated for 15 min 
with enzyme (1 pM trypsin; 1 nM HAT; 0.4 nM cathepsin L; 0.2 nM cathepsin B; or 5 nM cathepsin 
F). Next, the substrate (Enzo Life Sciences) was added, i.e. 50 µM and 80 µM Boc-Gln-Ala-Arg-
AMC for trypsin and HAT, respectively, or 10 µM Z-Phe-Arg-AMC for cathepsin B, F and L. The 
rising fluorescence signal (ex: 380 nm, em: 460 nm) was monitored during 60 min. 
4.30. Molecular modeling 
Multiple sequence alignment. The amino acid sequence of H1N1, H1N2, H2N2, H3N2, H5N1, 
H6N1, H7N2, H7N3, H7N7, H7N9, H9N2, and H10N8 were aligned by using Clustal Omega (ver-
sion 1.2.4; [47, 48]).  A subtype multiple sequence alignment was also performed for two variants of 
A/PR/8 H1N1 and two variants of the pandemic A/Virginia-ATCC-2009 H1N1. 
Molecular docking. Docking was performed using Glide [39, 40] with the standard precision mode 
to explore the potential binding of compound 2 to sites A, B, and C in A/PR/8 H1N1 HA. Docking 
in sites B and C was performed using the PDB structure 1RU7 of A/PR/8. For site A, the homology 
model of A/PR/8 in an “open” conformation (based on PDB entry 3EYM) produced in a previous 
work [13] was used. A cubic grid of 25 Å was applied to define each of the three binding sites. A 
RMSD value of 1.0 Å and an atom displacement of 2.6 were set to filter poses during clustering. A 
total of 50 poses were generated per ligand and four clusters were identified for each of the three 




Molecular dynamics simulations. Amber16 [49] was used to perform MD simulations on the select-
ed ligand–protein complex previously generated by docking analysis. The general Amber force field 
(GAFF) was used to parameterize the ligand [50], and the partial charges were derived at the 
B3LYP/6-31G(d) level, after preliminary optimization of the molecular structure, by using the re-
strained electrostatic potential (RESP) fitting method [51] implemented in Gaussian09 [52] and An-
techamber. The A/PR/8/34 complex with compound 2 (cluster 1) obtained in site C was solvated 
with a truncated octahedral (TIP3P) [53] water box with a layer of 18 Å and neutralized by adding 
Na+ ions. For the protein, disulphide bonds were built by using the “bond” command in tleap. 
Energy minimization was accomplished in three-stages that involved firstly all hydrogen atoms, then 
water molecules, and finally all the system with a maximum number of minimization cycles of 
10,000 for the latter stage. The minimized system was then heated from 0 to 300 K in five steps, the 
first being performed at constant volume and the rest at constant pressure. The system was then 
equilibrated for 5 ns at constant pressure. Langevin dynamics with a collision frequency of 1.0 ps-1 
was applied for temperature regulation during the heating. A force constant of 10 kcal mol-1 Å-2 was 
applied to restrain some protein-ligand contacts and thus avoid conformational distortions during 
heating and equilibration. These harmonic restraints were gradually eliminated during the first 50 ns 
of MD production. A total of 150 ns (50 for each MD replica) of un-restrained MD production was 
generated at constant volume and temperature in periodic boundary conditions.  
The SHAKE algorithm [54] was applied to constrain bonds involving hydrogen atoms. Cut-off for 
non-bonded interactions was set to 10 Å. Electrostatic interactions beyond the cut-off within the pe-
riodic box were computed by applying the Particle Mesh Ewald (PME) method [55]. The weak-
coupling algorithm with a time constant of 10.0 ps was used to stabilize the temperature during the 
simulation. 
Binding free energy. MMPBSA.py was used to compute the the binding free energy of compound 2. 
The method estimates the free energy (G ) of the protein-ligand complex, and the separate protein 





G = Egas +Gsolv −TS           (1) 
Egas = Eint + Eelec + EvdW           (2) 
Gsolv =GGB +GSURF           (3) 
where Eint , Eelec and EvdW  are the internal, Coulomb and van der Waals energy components in the gas 
phase, GGB  is the polar contribution, which was evaluated by using the generalized Born solvation 
model, and GSURF  stands for the nonpolar term, which was determined using a linear dependence on 
the solvent-accessible surface area ( SASA ; Eq. 4). 
 
GSURF = γSASA+b           (4) 
where the surface tension (γ ) is set to 0.0072 Kcal mol-1 Å-2, and b  is a correction term that was 
assumed to be zero in present calculations. 
 
The binding free energy (ΔGbind ) was evaluated as noted in Eq. 5. 
ΔGbind = Gcomplex − Gprotein − Gligand         (5) 
where Gx  is the average value determined for each species (x: complex, protein, ligand) using an 
ensemble of 100 snapshots taken from the last 50 ns of the MD trajectory of the complex within the 
framework of the single-trajectory approach. The vibrational entropy term was not determined since 
it was assumed to cancel out in the comparison between the three complexes. 
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Boc, tert-butoxycarbonyl, Cbz, benzyloxycarbonyl, CC50, 50% cytotoxic concentration, CCTLC, 
preparative centrifugal circular thin-layer chromatography, CPE, cytopathic effect, EC50, 50% effec-
tive concentration, HA, hemagglutinin, HAT, human airway trypsin-like protease, IC50, 50% inhibi-
tory concentration, MCC, minimum cytotoxic concentration, MD, molecular dynamics, MDCK, 
Madin-Darby canine kidney cells, MPLC, medium pressure liquid chromatography, PBS, phosphate 
buffered saline, PME, particle mesh Ewald method, RBC, red blood cell, SAR, structure-activity 
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